Bruker Announces MALDI PharmaPulse™, a Breakthrough High-Throughput Screening (HTS) Solution for Drug Discovery

Business News
Print
ST. LOUIS--(BUSINESS WIRE)--At the 63rd ASMS Conference on Mass Spectrometry and Allied Topics, Bruker (NASDAQ: BRKR) today announced a new high-throughput screening (HTS) solution designed to help pharmaceutical companies achieve high throughput, lower cost and higher specificity in drug discovery. The new MALDI PharmaPulse™ solution combines the speed, sensitivity and ease-of-use of Bruker’s robust MALDI-TOF systems with industry-leading HTS robotics and automation software from HighRes Bioso

imageimage
image

Read more